We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genomic Atlas of Human Plasma Proteome Publicized

By LabMedica International staff writers
Posted on 26 Jun 2018
Although plasma proteins have important roles in biological processes and are the direct targets of many drugs, the genetic factors that control inter-individual variation in plasma protein levels are not well understood.

Bringing in expression quantitative trait locus (QTL) and protein QTL data, biological pathway clues, drug database insights, and variants identified in prior genome-wide association studies, a team of scientists subsequently searched for plasma proteins contributing to common conditions, such as inflammatory bowel disease, as well as for potential drugs for altering these pathways.

A large team of scientists collaborating with those at the University of Cambridge (Cambridge, UK) characterized the genetic architecture of the human plasma proteome in healthy blood donors. More...
The study involved about 50,000 participants, and the team systematically quantified levels for thousands of proteins in plasma samples from 3,301 seemingly healthy, genotyped individuals. With these data, they uncovered more than 1,900 interactions between almost 800 genomic regions and nearly 1,500 proteins.

The scientists used the SOMAscan, an aptamer-based multiplex protein assay. They quantified plasma levels of 3,622 proteins in blood samples from 3,301 healthy donors. They set those proteome data alongside genetic profiles for the participants, searching for associations between plasma proteins and 10.6 million autosomal SNPs that were imputed or directly assessed using Affymetrix Axiom UK Biobank arrays. The team's analysis uncovered 1,927 associations involving 1,478 proteins and 764 regions in the genome. Most of those associations, 89%, had not been described previously.

The team noted that 502 of the protein-associated loci appeared to act locally, or in cis, while 228 had trans effects on plasma proteins. The remaining 34 loci appeared to have both cis and trans protein interactions. They validated 106 of 163 proposed protein QTLs using an Olink protein assay (Uppsala, Sweden; www.olink.com) on samples from another 4,998 individuals, noting that the cis pQTLs appeared more apt to replicate than those involving longer-range trans interactions. After exploring the overlap between the proposed pQTLs and expression QTLs reported in the past, the investigators incorporated information from prior genome-wide association study.

The authors concluded that by linking genetic factors to diseases via specific proteins, their analyses highlight potential therapeutic targets, opportunities for matching existing drugs with new disease indications, and potential safety concerns for drugs under development. The study was published on June 6, 2018, in the journal Nature.

Related Links:
University of Cambridge


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.